CNS Drug Delivery Summit 2023: Biocytogen to Showcase Payload Brain Delivery of Fully Human TFR1 HCAbs

Biocytogen’s antibody BD & Licensing team will present a poster entitled “Discovery of RenNano^®-derived human heavy-chain-only TFR1 antibodies that can efficiently cross the blood-brain barrier and deliver drug payloads” at the upcoming 5th annual CNS Drug Delivery Summit, held in Boston, US from December 5-7, 2023. 

TFR1 heavy-chain-only antibodies (HCAbs) discovered from Biocytogen’s proprietary fully human nanobody mice (RenNano^® mice) demonstrate optimal in vitro nM range affinity and internalization capacity. In vivo experiments further show that the HCAbs can efficiently cross the blood-brain barrier and deliver payloads with favorable pharmacokinetic properties, making them ideal for future drug development.

The ability of RenNano^® mice to generate diverse HCAb sequences with favorable affinity facilitates the discovery of fully human nanobodies with reduced time, cost and risk, as in vitro humanization is not necessary. In addition to the potential to be developed into nanobodies with superior tissue penetration ability, RenNano-derived HCAbs can also be directly assembled into bi-/multi-specific antibodies or cell therapies.

The development of RenNano^® mice led to the launch of Biocytogen’s “Nano 100 Project” early this year, which aims to develop fully human nanobody drugs for more than 100 targets, including tumor associated antigens (TAAs), immune-checkpoints, cytokines, GPCRs, and factors related to neurological diseases. In addition to TFR1, fully human nanobody sequences for more than 20 targets have been obtained in the chart below. To learn more about Biocytogen’s off-the-shelf nanobodies, or to start a novel nanobody discovery project, stop by the poster or contact our team at [email protected].

Targets with nanobody sequences available:

Event Date: December 5-7 | Event Location: Boston, MA